Home › Heart Failure › NCT07435662
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of HFrEF (EF ≤ 40%) * Receiving care within DHHA system Exclusion Criteria: * Estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73 m² or receiving dialysis. * Cirrhosis * Inability to consent * Non-English or non-Spanish speaking
About the study
Numerous pharmacotherapies have been proven to reduce mortality and hospitalization rates for heart failure with reduced ejection fraction (HFrEF) patients. However, these are underutilized clinically, preventing realization of proven benefits. Simplified patient education tools and multidisciplinary teams including pharmacists have been used to improve medication optimization but in predominantly private payer groups. This study will translate these evidence-based interventions to patients with limited access to care. In this randomized, prospective study, patients with HFrEF at a local hospital dedicated to care for participants with limited access will receive either pharmacist-directed medication adjustment visits with patient education materials or standard of care. This study will assess the hypothesis that the implementation of the intervention is feasible in this population, as demonstrated by the number of visits and proportion of visits with medication adjustments. Further, medication dosing in each arm will be evaluated via the Kansas City Medication Optimization (KCMO) score, which will average the percentage of maximal doses of appropriate HFrEF medication classes a patient is on. The change in KCMO scores over the course of the pilot in the two arms will then be compared to assess the hypothesis that the intervention will better increase patients' KCMO scores than the standard of care. The findings of this study will help address knowledge gaps in the care of patients not well represented previously in the literature. This proposal addresses the translational science roadblock of recruitment and engagement of participants with limited access to care.
What is being tested
- Pharmacy follow up (other)
Sponsor: Denver Health and Hospital Authority · Participants: 40 · Started: Oct 1, 2025
Contact the study team
- Ryan C Martin, MD, MPH · Phone: 303-602-3899
Official record on ClinicalTrials.gov — NCT07435662
Locations in the U.S.
| Colorado | Denver Health and Hospital Authority, Denver |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.